Refractory Solid Tumors Clinical Trials

36 clinical trials for Refractory Solid Tumors across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors — RECRUITING · PHASE1
• Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors — RECRUITING
• A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors — RECRUITING · PHASE1
• Personalized KSX01-TCRT in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• KSX01-TCRT Injection Project in Solid Tumors — RECRUITING · PHASE1
• KSH01-TCRT Solid Tumors — RECRUITING · PHASE1
• This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. — OTHER · PHASE1
• Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children — COMPLETED · PHASE1
• A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) — TERMINATED · PHASE1
• TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) — COMPLETED · PHASE1
• A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma — COMPLETED · PHASE1
• Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors — COMPLETED · PHASE1
• MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors — OTHER
• A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval — COMPLETED · PHASE1
• Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors — OTHER · PHASE1
• Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors — COMPLETED · PHASE4
• Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors — COMPLETED · NA
• Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors — COMPLETED · PHASE4
• Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors — COMPLETED · NA
• Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors — COMPLETED · NA
• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors — COMPLETED · PHASE1
• Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation — OTHER · PHASE2
• Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer — TERMINATED · PHASE1
• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 — COMPLETED · PHASE1
• A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors — COMPLETED · PHASE1
• Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors — WITHDRAWN · NA
• Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors — COMPLETED · NA
• A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors — TERMINATED · PHASE1
• A Phase I/Expansion Study of Dasatinib — TERMINATED · PHASE1
• Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia — COMPLETED · PHASE1
• Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment — COMPLETED · PHASE1
• PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors — COMPLETED · PHASE1
• A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors — WITHDRAWN · NA
• An Open-Label, Dose-Escalation Study of AZD2461 — COMPLETED · PHASE1
• Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors — COMPLETED · PHASE1
• A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors — COMPLETED · PHASE2

Refine this search